logo

For the Inventor, By the Inventor

Nutley, NJ, United States of America

Marek Michal Kabat

This inventor holds 6 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2001-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marek Michal Kabat. Retrieved from https://idiyas.com/inventor/marek-michal-kabat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 50.0

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 40(Granted Patents)


Company Filing History:

goldMedal6 out of 5,024 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 2001-2006

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7112676 - Pyrimido compounds having antiproliferative activity (2006-09-26),
2. 7084270 - Pyrimido compounds having antiproliferative activity (2006-08-01),
3. 6603030 - Process for producing phosphineoxide vitamin D precursors (2003-08-05),
4. 6353123 - Process and intermediates useful to produce vitamin D analogs (2002-03-05),
5. 6294688 - Process useful to produce vitamin D analogs (2001-09-25),
6. 6291694 - Process and intermediates useful to produce vitamin D analogs (2001-09-18),

Title: The Innovative Contributions of Marek Michal Kabat

Introduction

Marek Michal Kabat is a notable inventor based in Nutley, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential applications in cancer treatment. With a total of 6 patents to his name, Kabat's work is recognized for its innovative approach to addressing serious health issues.

Latest Patents

Kabat's latest patents focus on novel pyrimido compounds that exhibit antiproliferative activity. These compounds are selective inhibitors of both KDR and FGFR kinases, while also being selective against LCK. The compounds and their pharmaceutically acceptable salts serve as anti-proliferative agents that are useful in the treatment or control of solid tumors, including breast, colon, lung, and prostate tumors. Additionally, the patents disclose pharmaceutical compositions containing these compounds and methods for treating cancer.

Career Highlights

Marek Michal Kabat is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at the company has allowed him to focus on innovative research and development, contributing to advancements in cancer therapies.

Collaborations

Kabat has collaborated with several esteemed colleagues, including Andrzej Robert Daniewski and Masami Okabe. These collaborations have further enriched his research and development efforts in the pharmaceutical field.

Conclusion

Marek Michal Kabat's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to advancing cancer treatment. His work continues to inspire and pave the way for future innovations in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…